Companies House 12760856 2025-07-31 2025-07-31 2024-08-01 false iso4217:GBP xbrli:pure 12760856 2023-08-01 2024-07-31 12760856 2025-07-31 12760856 2024-08-01 2025-07-31 12760856 2024-07-31 12760856 curr:PoundSterling 2024-08-01 2025-07-31 12760856 uk-bus:CompanyLimitedByGuarantee 2024-08-01 2025-07-31 12760856 uk-bus:FRS102 2024-08-01 2025-07-31 12760856 uk-bus:AuditExempt-NoAccountantsReport 2024-08-01 2025-07-31 12760856 uk-bus:FullAccounts 2024-08-01 2025-07-31 12760856 uk-bus:RegisteredOffice 2024-08-01 2025-07-31 12760856 uk-bus:Director1 2024-08-01 2025-07-31 12760856 uk-bus:Director2 2024-08-01 2025-07-31 12760856 uk-bus:Director3 2024-08-01 2025-07-31 12760856 uk-bus:Director4 2024-08-01 2025-07-31 12760856 uk-bus:Director5 2024-08-01 2025-07-31 12760856 uk-bus:Director6 2024-08-01 2025-07-31 12760856 uk-bus:Director7 2024-08-01 2025-07-31 12760856 uk-bus:Director8 2024-08-01 2025-07-31 12760856 uk-bus:Director9 2024-08-01 2025-07-31 12760856 uk-bus:Director10 2024-08-01 2025-07-31 12760856 uk-bus:Director11 2024-08-01 2025-07-31 12760856 uk-bus:Director12 2024-08-01 2025-07-31 12760856 uk-bus:Director13 2024-08-01 2025-07-31 12760856 uk-bus:Director14 2024-08-01 2025-07-31 12760856 uk-bus:Director15 2024-08-01 2025-07-31 12760856 uk-bus:Director16 2024-08-01 2025-07-31 12760856 uk-bus:Director17 2024-08-01 2025-07-31 12760856 uk-bus:Director18 2024-08-01 2025-07-31 12760856 uk-bus:Director19 2024-08-01 2025-07-31 12760856 uk-bus:Director20 2024-08-01 2025-07-31 12760856 uk-bus:Director21 2024-08-01 2025-07-31 12760856 uk-bus:CompanySecretary1 2024-08-01 2025-07-31 12760856 core:AfterOneYear 2025-07-31 12760856 core:AfterOneYear 2024-07-31 12760856 core:WithinOneYear 2025-07-31 12760856 core:WithinOneYear 2024-07-31 12760856 core:WithinOneYear 2024-08-01 2025-07-31 12760856 core:AfterOneYear 2025-07-31 12760856 core:AfterOneYear 2024-07-31 12760856 core:AfterOneYear 2024-08-01 2025-07-31 12760856 core:ShareCapital 2025-07-31 12760856 core:ShareCapital 2024-07-31 12760856 core:SharePremium 2025-07-31 12760856 core:SharePremium 2024-07-31 12760856 core:OtherReservesSubtotal 2025-07-31 12760856 core:OtherReservesSubtotal 2024-07-31 12760856 core:RevaluationReserve 2025-07-31 12760856 core:RevaluationReserve 2024-07-31 12760856 core:RetainedEarningsAccumulatedLosses 2025-07-31 12760856 core:RetainedEarningsAccumulatedLosses 2024-07-31 12760856 1 2024-08-01 2025-07-31 12760856 2 2024-08-01 2025-07-31 12760856 3 2024-08-01 2025-07-31 12760856 core:LandBuildings 2024-08-01 2025-07-31 12760856 core:LandBuildings 2025-07-31 12760856 core:LandBuildings 2023-08-01 2024-07-31 12760856 core:LandBuildings 2024-07-31 12760856 core:PlantMachinery 2024-08-01 2025-07-31 12760856 core:PlantMachinery 2025-07-31 12760856 core:PlantMachinery 2023-08-01 2024-07-31 12760856 core:PlantMachinery 2024-07-31 12760856 core:FurnitureFittingsToolsEquipment 2024-08-01 2025-07-31 12760856 core:FurnitureFittingsToolsEquipment 2025-07-31 12760856 core:FurnitureFittingsToolsEquipment 2023-08-01 2024-07-31 12760856 core:FurnitureFittingsToolsEquipment 2024-07-31 12760856 core:OfficeEquipment 2024-08-01 2025-07-31 12760856 core:OfficeEquipment 2025-07-31 12760856 core:OfficeEquipment 2023-08-01 2024-07-31 12760856 core:OfficeEquipment 2024-07-31 12760856 core:Vehicles 2024-08-01 2025-07-31 12760856 core:Vehicles 2025-07-31 12760856 core:Vehicles 2023-08-01 2024-07-31 12760856 core:Vehicles 2024-07-31 12760856 core:NetGoodwill 2024-08-01 2025-07-31 12760856 core:NetGoodwill 2025-07-31 12760856 core:NetGoodwill 2023-08-01 2024-07-31 12760856 core:NetGoodwill 2024-07-31 12760856 core:IntangibleAssetsOtherThanGoodwill 2024-08-01 2025-07-31 12760856 core:IntangibleAssetsOtherThanGoodwill 2025-07-31 12760856 core:IntangibleAssetsOtherThanGoodwill 2023-08-01 2024-07-31 12760856 core:IntangibleAssetsOtherThanGoodwill 2024-07-31

# KINDLING THERAPIES CIC

## Company limited by guarantee

## Company Registration Number:
12760856 (England and Wales)

## Unaudited statutory accounts for the year ended 31 July 2025

## Period of accounts

## Start date: 1 August 2024

## End date: 31 July 2025

# KINDLING THERAPIES CIC

## Contents of the Financial Statements

for the Period Ended 31 July 2025

Balance sheet |
Additional notes |
Balance sheet notes |
Community Interest Report |

# KINDLING THERAPIES CIC

## Balance sheet

As at 31 July 2025

| Notes | 2025 | 2024
--- | --- | --- | ---
|  | £ | £
Current assets
Debtors: | 3 |  | 1,240
Cash at bank and in hand: |  | 6,180 | 2,010
Total current assets: |  | 6,180 | 3,250
Creditors: amounts falling due within one year: | 4 | ( 6,745 ) | ( 1,535 )
Net current assets (liabilities): |  | (565) | 1,715
Total assets less current liabilities: |  | (565) | 1,715
Creditors: amounts falling due after more than one year: | 5 | ( 2,962 ) | ( 2,962 )
Total net assets (liabilities): |  | (3,527) | (1,247)
Members' funds
Profit and loss account: |  | (3,527) | ( 1,247)
Total members' funds: |  | ( 3,527) | (1,247)

The notes form part of these financial statements

# KINDLING THERAPIES CIC

## Balance sheet statements

For the year ending 31 July 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen not to file a copy of the company's profit and loss account.

This report was approved by the board of directors on 31 January 2026
and signed on behalf of the board by:

Name: Clare Hunt
Status: Director

The notes form part of these financial statements

# KINDLING THERAPIES CIC

## Notes to the Financial Statements

for the Period Ended 31 July 2025

- ## 1. Accounting policies

  Basis of measurement and preparation

  These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

# KINDLING THERAPIES CIC

## Notes to the Financial Statements

for the Period Ended 31 July 2025

- ## 2. Employees

  | 2025 | 2024
  --- | --- | ---
  Average number of employees during the period | 0 | 0

# KINDLING THERAPIES CIC

## Notes to the Financial Statements

for the Period Ended 31 July 2025

## 3. Debtors

| 2025 | 2024
--- | --- | ---
| £ | £
Other debtors |  | 1,240
Total |  | 1,240

# KINDLING THERAPIES CIC

## Notes to the Financial Statements

for the Period Ended 31 July 2025

## 4. Creditors: amounts falling due within one year note

| 2025 | 2024
--- | --- | ---
| £ | £
Other creditors | 6,745 | 1,535
Total | 6,745 | 1,535

# KINDLING THERAPIES CIC

## Notes to the Financial Statements

for the Period Ended 31 July 2025

## 5. Creditors: amounts falling due after more than one year note

| 2025 | 2024
--- | --- | ---
| £ | £
Other creditors | 2,962 | 2,962
Total | 2,962 | 2,962

# COMMUNITY INTEREST ANNUAL REPORT

### KINDLING THERAPIES CIC

### Company Number: 12760856 (England and Wales)

### Year Ending: 31 July 2025

Company activities and impact

This year has seen positive changes for the company. Although there has been a drop in income, we have laid foundations for developments within the business. We changed our name to Kindling Therapies CIC, to increase the arts therapies we offer. Two of our directors changed – the directorship is now made up of two music therapists and one arts therapist. We set up socials and created a new website. We finished the SLA with Newcastle Hospitals NHS Foundation, so our funding has come through work in individual music and art therapy for Sunderland Together for Children and private work. At the end of the financial year we received a National Lottery grant which would enable us to use art and music therapy in a pilot project with a local charity, going into the next financial year.

Consultation with stakeholders

No consultation with stakeholders

Directors' remuneration

No remuneration was received

Transfer of assets

No transfer of assets other than for full consideration

This report was approved by the board of directors on
31 January 2026

And signed on behalf of the board by:
Name: Clare Hunt
Status: Director